Angiolayn: Transkateterny aortal valve

On February 7, 2019 it became known that the Angiolayn company showed to medical community of development in the field of treatment of diseases of a cardiovascular system, including the working model of the transkateterny aortal valve of heart and the system of delivery to it

The Transkateterny aortal valve – the bioprosthesis irreplaceable for patients with heart failure to whom traditional surgical interventions are contraindicated. Use of adaptation allows to reduce intervention in an organism of the patient and the related possible complications for health to a minimum: operation on implantation is performed using a catheter, without thorax section. Russia is used so far, generally foreign analogs, worth up to 1.5 million rubles. It is expected that development of the Novosibirsk specialists will cost several times cheaper. The need of the Russian medicine for such devices makes about 40 thousand pieces a year, and the number of implantations to patients does not exceed thousands, just because of the high price of import products.

Demand for transkateterny aortal valves in our country increases especially as the number of age diseases of valves of heart grows around the world, in process of natural aging of the population and increase in life expectancy. Besides, not only elderly patients, but also, for example, people of middle age face heart failure. However low-traumatic chreskozhny implantation of the valve is still unavailable to a wide range of patients in our country because of the high cost of tools. We aim to make the contribution to elimination of deficit of such products in our country: each following transaction using our products this execution in practice of a mission of Angiolayn company which sounds as - "more than the saved lives". Oleg Volkov, medical director of Angiolayn LLC